Drugmax, Inc. (Nasdaq: DMAX) - B2B pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Drugmax, Inc. (Nasdaq: DMAX) - B2B pharmaceuticals

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jeff Grossman who wrote (2)	11/29/1999 2:09:00 PM
From: Jeff Grossman	Read Replies (1) of 20

Some heavy selling hit DMAX last Wednesday and knocked the price down below its $10 offering price. But somebody, probably the underwriter, held strong at $9.625 and took in A LOT of stock at that price. Once the selling dried up, the price moved back over $10. Currently, it's about $11. The company announced today that it completed its acquisition of Becan Distributors, Inc., a wholesale distributor of pharmaceutical and over-the-counter products. Becan had net revenues for the six months ended September 30, 1999 of $26.5 million. biz.yahoo.com Jeff

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next